Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Vivoryon Therapeutics N.V. has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer's disease, inflammatory and fibrotic disorders, including of the kidney, and cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	32.13M 36.85M 30.26M 27.56M 51.67M 3.53B 51.74M 362M 140M 1.8B 138M 135M 5.8B	P/E 2026 *	-2.86x	P/E 2027 *	-2.93x
Enterprise Value	36.45M 41.81M 34.33M 31.27M 58.62M 4.01B 58.69M 411M 158M 2.04B 157M 154M 6.58B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	82.01%	Yield 2026 *	-	Yield 2027 *	-

08-06	Vivoryon Therapeutics N.V., H1 2026 Earnings Call, Aug 06, 2026
08-06	Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-23	Vivoryon Therapeutics N.V., 2025 Earnings Call, Apr 23, 2026
04-23	Vivoryon Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-22	Vivoryon Therapeutics N.V. Auditor Raises 'Going Concern' Doubt	CI
03-28	Vivoryon Therapeutics N.V. Provides Update On Growing Body Of Evidence Validating Glutaminyl Cyclases As Promising Targets In DKD	CI
12-04	Vivoryon Therapeutics N.V., Q3 2025 Earnings Call, Dec 04, 2025
25-10-30	Vivoryon Therapeutics N.V. announced that it has received ?5.07075 million in funding	CI
25-10-07	Vivoryon Therapeutics Raises EUR5 Million via Private Share Placement	MT
25-09-04	Vivoryon Therapeutics N.V., H1 2025 Earnings Call, Sep 04, 2025
25-09-04	Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-06-17	Vivoryon Therapeutics N.V., Q1 2025 Earnings Call, Jun 17, 2025
25-05-27	Vivoryon Therapeutics Obtains Additional US Patent for Varoglutamstat	MT

08-18	Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026	GL
08-06	Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update	GL
07-23	Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026, Annual General Meeting Planned for End of September 2026	AQ
07-22	Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026	GL
07-20	Vivoryon Therapeutics N : C. Christiansen - Vivoryon Therapeutics N.V. - Halle	PU

08-06	Vivoryon boekt kleiner halfjaarverlies
08-03	Unternehmenskalender vom 3. bis 7. August 2026
07-20	Vivoryon Therapeutics N : C. Christiansen - Vivoryon Therapeutics N.V. - Halle
06-11	Verlies Vivoryon slinkt
04-26	Sterke week voor chippers op Damrak

Manager	Title	Age	Since
Frank Weber CEO	Chief Executive Officer	66	2023-08-13
Anne Doering DFI	Director of Finance/CFO	-	2024-02-29
Julia Neugebauer COO	Chief Operating Officer	-	2025-04-30

Vivoryon Therapeutics AG Stock Euronext Amsterdam

Stocks

DE0007921835

Biotechnology & Medical Research

Valuation: Vivoryon Therapeutics AG

Latest news: Vivoryon Therapeutics AG

Last Transcript: Vivoryon Therapeutics AG

Press Releases: Vivoryon Therapeutics AG

News in other languages: Vivoryon Therapeutics AG

Quotes and Performance

Managers and Directors: Vivoryon Therapeutics AG

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Charlotte Lohmann BRD	Director/Board Member	56	2006-12-31
Frank Weber BRD	Director/Board Member	66	2023-09-14
Michael Schaeffer BRD	Director/Board Member	58	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIVORYON THERAPEUTICS AG	-1.26%	-.--%	-	-	37.02M
LONZA GROUP AG	+0.59%	+2.73%	+1.03%	+28.74%	46.28B
IQVIA HOLDINGS INC.	+1.30%	+1.58%	+44.15%	+35.50%	43.85B
REVOLUTION MEDICINES, INC.	+0.95%	-6.02%	+342.72%	+532.41%	40.93B
BEONE MEDICINES AG	+4.23%	+3.35%	+9.35%	+94.73%	39.89B
CELLTRION, INC.	+1.11%	+1.45%	+11.52%	+45.96%	29.5B
MEDPACE HOLDINGS, INC.	+1.94%	+4.84%	+25.19%	+159.21%	17.09B
ASCENDIS PHARMA A/S	+0.37%	-10.32%	-	-	15.55B
EUROFINS SCIENTIFIC SE	+2.12%	+8.18%	+24.78%	+41.21%	15.22B
TEMPUS AI, INC.	+0.24%	+25.43%	-11.57%	-	14.05B
Average	+1.14%	+3.23%	+55.90%	+133.97%	29.15B
Weighted average by Cap.	+1.51%	+1.71%	+70.37%	+142.46%

	2026 *	2027 *
Net sales	-	-
Net income	-10.4M -11.93M -9.8M -8.92M -16.72M -1.14B -16.75M -117M -45.21M -582M -44.81M -43.81M -1.88B	-10.4M -11.93M -9.8M -8.92M -16.72M -1.14B -16.75M -117M -45.21M -582M -44.81M -43.81M -1.88B
Net Debt	4.32M 4.95M 4.07M 3.71M 6.95M 475M 6.96M 48.73M 18.78M 242M 18.61M 18.2M 780M	13.03M 14.94M 12.27M 11.18M 20.95M 1.43B 20.98M 147M 56.65M 729M 56.14M 54.89M 2.35B